Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025

Camille Vatier¹, David Araújo-Vilar², Baris Akinci³, Thierry Arnould⁴, Carine Beaupère⁵, Elise Bismuth⁶, Rebecca J Brown⁷, Giovanni Ceccarini⁸, Philippe Collas⁹, Alessandra Gambineri¹⁰, Donatella Gilio⁸, Sharon Halperin¹¹, Sonja Janmaat¹², Sophie Lamothe¹², Giovanna Lattanzi¹³, Margherita Maffei¹⁴, Ormond A MacDougald¹⁵, Héléna Mosbah¹⁶, Estelle Nobecourt¹⁷, Elif A Oral¹⁸, Justin Rochford¹⁹, Ferruccio Santini⁸, Eric C Schirmer²⁰, Julia von Schnurbein²¹, Robert Semple²², Daniel Tews²¹, Martin Wabitsch²¹, Marie-Christine Vantyghem²³, Corinne Vigouroux²⁴

Affiliations

¹ Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France; Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France.
² UETeM-Molecular Pathology Group, Department of Medicine, IDIS-CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
³ DEPARK, Dokuz Eylul University Health Campus & Izmir Biomedicine and Genome Center (IBG), Izmir, Turkey.
⁴ Laboratory of Biochemistry and Cell Biology (URBC), NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, Namur, Belgium.
⁵ Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France.
⁶ Assistance Publique-Hôpitaux de Paris, Robert-Debré University Hospital, Department of Pediatric Endocrinology and Diabetology, Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris-Cité University, European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France.
⁷ National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
⁸ Obesity and Lipodystrophy Center, Department of Clinical and Experimental Medicine, Endocrinology Unit, University Hospital of Pisa, European Reference Network for Rare Endocrine Conditions (Endo-ERN), and European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), Pisa, Italy.
⁹ Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
¹⁰ Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, European Reference Network for Rare Endocrine Conditions (Endo-ERN), Bologna, Italy.
¹¹ Lipodystrophy United, Tel Aviv, Israel.
¹² Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France.
¹³ University of Bologna, CNR-National Research Council of Italy, Institute of Molecular Genetics « Luigi Luca Cavalli-Sforza » Unit of Bologna, Bologna, Italy; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
¹⁴ Institute of Clinical Physiology, National Research Council, National Institute of Nuclear Physics (INFN), Pisa, Italy.
¹⁵ Department of Molecular & Integrative Physiology, and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
¹⁶ Department of Endocrinology, University Hospital La Milétrie, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Poitiers, France.
¹⁷ University Hospital of Nancy, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Nancy, France.
¹⁸ Division of Metabolism, Endocrinology & Diabetes and Caswell Diabetes Institute, University of Michigan, Ann Arbor, MI, USA.
¹⁹ The Rowett Institute and Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Aberdeen, United Kingdom.
²⁰ Institute of Cell Biology, University of Edinburgh, EH9 3BF Edinburgh, United Kingdom.
²¹ Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, European Reference Network for Rare Endocrine Conditions (Endo-ERN), Ulm, Germany.
²² Centre for Cardiovascular Science, MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
²³ Department of Endocrinology-Metabolism, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Lille University Hospital, and Inserm U1190 - EGID, Institut Pasteur de Lille, Lille University, Lille, France.
²⁴ Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France; Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France. Electronic address: corinne.vigouroux@inserm.fr.

PMID: 40749787
DOI: 10.1016/j.ando.2025.102432

Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025

Camille Vatier et al. Ann Endocrinol (Paris). 2025.

. 2025 Jul 30;86(5):102432.

doi: 10.1016/j.ando.2025.102432. Online ahead of print.

Authors

Affiliations

¹ Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France; Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France.
² UETeM-Molecular Pathology Group, Department of Medicine, IDIS-CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
³ DEPARK, Dokuz Eylul University Health Campus & Izmir Biomedicine and Genome Center (IBG), Izmir, Turkey.
⁴ Laboratory of Biochemistry and Cell Biology (URBC), NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, Namur, Belgium.
⁵ Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France.
⁶ Assistance Publique-Hôpitaux de Paris, Robert-Debré University Hospital, Department of Pediatric Endocrinology and Diabetology, Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Paris-Cité University, European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France.
⁷ National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
⁸ Obesity and Lipodystrophy Center, Department of Clinical and Experimental Medicine, Endocrinology Unit, University Hospital of Pisa, European Reference Network for Rare Endocrine Conditions (Endo-ERN), and European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), Pisa, Italy.
⁹ Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
¹⁰ Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, European Reference Network for Rare Endocrine Conditions (Endo-ERN), Bologna, Italy.
¹¹ Lipodystrophy United, Tel Aviv, Israel.
¹² Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France.
¹³ University of Bologna, CNR-National Research Council of Italy, Institute of Molecular Genetics « Luigi Luca Cavalli-Sforza » Unit of Bologna, Bologna, Italy; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
¹⁴ Institute of Clinical Physiology, National Research Council, National Institute of Nuclear Physics (INFN), Pisa, Italy.
¹⁵ Department of Molecular & Integrative Physiology, and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
¹⁶ Department of Endocrinology, University Hospital La Milétrie, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Poitiers, France.
¹⁷ University Hospital of Nancy, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Nancy, France.
¹⁸ Division of Metabolism, Endocrinology & Diabetes and Caswell Diabetes Institute, University of Michigan, Ann Arbor, MI, USA.
¹⁹ The Rowett Institute and Aberdeen Cardiovascular and Diabetes Centre, University of Aberdeen, Aberdeen, United Kingdom.
²⁰ Institute of Cell Biology, University of Edinburgh, EH9 3BF Edinburgh, United Kingdom.
²¹ Center for Rare Endocrine Diseases, Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, European Reference Network for Rare Endocrine Conditions (Endo-ERN), Ulm, Germany.
²² Centre for Cardiovascular Science, MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
²³ Department of Endocrinology-Metabolism, Center for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Lille University Hospital, and Inserm U1190 - EGID, Institut Pasteur de Lille, Lille University, Lille, France.
²⁴ Assistance Publique-Hôpitaux de Paris (AP-HP), Saint-Antoine University Hospital, Endocrinology Department, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), European Reference Network for Rare Endocrine Conditions (Endo-ERN Assistance-Publique Consortium), Paris, France; Sorbonne University, Saint-Antoine Research Center, Inserm UMR_S938, Paris, France. Electronic address: corinne.vigouroux@inserm.fr.

PMID: 40749787
DOI: 10.1016/j.ando.2025.102432

Abstract

Lipodystrophy syndromes are rare diseases characterized by anatomical and functional defects of adipose tissue, frequently leading to severe insulin resistance-associated metabolic complications. Subtypes of lipodystrophy syndromes differ in: their clinical presentation, with generalized or partial loss of adipose tissue; in their origin, either genetic or acquired; and in their comorbidities, forming a heterogeneous group of disorders of different severity. The European Consortium of Lipodystrophies (ECLip) was founded in 2014 as a non-profit network of health professionals, scientists and patient associations. ECLip aims to promote international collaborations to increase pathophysiological and clinical knowledge, and improve the management of lipodystrophy syndromes. ECLip now comprises 59 groups from 30 countries from Europe and beyond. The consortium developed in parallel to the increased awareness of clinical diagnosis, the growing scientific interest for these diseases at the crossroads between adipose tissue biology, whole body metabolism, genetics and immunity, and to the emergence of new pharmacological approaches. The ECLip congress, held every 18 months, aims to discuss the recent achievements and projects in the field of lipodystrophies, to consolidate ECLip activities and to promote future collaborations, highlighting clinical and fundamental aspects as well as patients' perspectives. Oral communications presented during the meeting in Paris, France, in 2025 are summarized in these minutes.

Keywords: Adipocytes; Auto-immunity; Cardiovascular disease; Caveolin-1; Cellular senescence; Chromatin; Diet; Epidemiology; Laminopathies; Leptin; Lipidomic; Lipodystrophy; Metabolism; Mitochondria; Natural history; POLD1; Quality of life; Registry; Seipin; Therapies.

PubMed Disclaimer

Conflict of interest statement

Disclosure of interest Camille Vatier reports boards, symposia and congress invitations from Abbott, Advanz Pharma, Amryt, Astra-Zeneca, Eli Lilly, HRA, LVL, Novartis, Novo-Nordisk, Sanofi, Regeneron, and Vitalaire. David Araújo-Vilar speaker has received honorarium as expert advisor from Amryt Pharma. Baris Akinci has run projects for and/or served as a consultant, board member, steering committee member, and/or speaker to Amryt Pharmaceuticals (wholly owned subsidiary of Chiesi Farmaceutici S.p.A.), Alnylam, Regeneron, ThirdRock Ventures, Astra Zeneca, Novonordisk, Boehringer Ingelheim, Sanofi, Bilim Ilac, ARIS, and Servier. Elif Oral received advisory/consultancy fees from Amryt Pharmaceuticals and Chiesi, the current owner of metreleptin, formerly Aegerion Pharmaceuticals, Third Rock Ventures, and Rejuvenate Bio and is an inventor on the method of use patent for “metreleptin in the treatment of lipoatrophy, lipodystrophy, lipoatrophic diabetes and related conditions”. She served as a consultant to Ionis Pharmaceuticals, Rhythm Pharmaceuticals and Regeneron Pharmaceuticals through payments made to the University of Michigan. Justin Rochford is co-inventor on a patent application for the use of gene therapies for treating lipodystrophies. Julia v. Schnurbein reports relationships with Aegerion/Amryt Pharmaceuticals then Chiesi Farmaceutici, Rhythm Pharmaceuticals and Sanofi for consulting or advisory, with Ipsen, Novo Nordisk, Serono, Merck, Sanofi for travel reimbursement. Marie Christine Vantyghem and Corinne Vigouroux serve as investigators in the APL-22 clinical study and Elise Bismuth in the APL-20 clinical study sponsored by Chiesi Farmaceutici. Corinne Vigouroux reports previous lecture fees from Amryt Pharmaceuticals (now Chiesi Farmaceutici), Sanofi and Gilead.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Masson (France)

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025

Affiliations

Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20-21 May 2025

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

LinkOut - more resources

Full Text Sources